G. J. Mirjam Groenewold

G. J. Mirjam Groenewold

Auto-generated profile, based on publicly available information

G. J. Mirjam Groenewold

Molecular Virology Laboratory, Leiden University Center for Infectious Diseases, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Nature
Verified
Journal Article
Open access
PDF file
MLManon Laporte
Manon Laporte
DJDIRK JOCHMANS
DIRK JOCHMANS
DBDorothée Bardiot
Dorothée Bardiot
LDLowiese Desmarets
Lowiese Desmarets
ODOliver J. Debski-Antoniak
Oliver J. Debski-Antoniak
JNJohan Hendrik Neyts
Johan Hendrik Neyts
The coronavirus membrane protein (M) is the main organizer of coronavirus assembly1,2,3. Here, we report on an M-targeting molecule, CIM-834, that blocks the assembly of SARS-CoV-2. CIM-834 was obtained through high-throughput phenotypic antiviral screening followed by medicinal-chemistry efforts and target elucidation. CIM-834 inhibits the replication of SARS-CoV-2 (including a broad panel of variants) and SARS-CoV. In SCID mice and Syrian hamsters intranasally infected with SARS-CoV-2, oral treatment reduced lung viral titres to nearly undetectable levels, even (as shown in mice) when treatment was delayed until 24 h before the end point. Treatment of infected hamsters prevented transmission to untreated sentinels. Transmission electron microscopy studies show that virion assembly is completely absent in cells treated with CIM-834. Single-particle cryo-electron microscopy reveals that CIM-834 binds and stabilizes the M protein in its short form, thereby preventing the conformational switch to the long form, which is required for successful particle assembly. In conclusion, we have discovered a new druggable target in the replication cycle of coronaviruses and a small molecule that potently inhibits it.

26 May 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MPMiriam Porzberg
Miriam Porzberg
GGG.J. Mirjam Groenewold
G.J. Mirjam Groenewold
HLHeyrhyoung Lyoo
Heyrhyoung Lyoo
AJAlexander K.M.H. Jakob
Alexander K.M.H. Jakob
WTWillem H.C. Titulaer
Willem H.C. Titulaer
FRFloris P. J. T. Rutjes
Floris P. J. T. Rutjes
Five years after the onset of the COVID-19 pandemic, there still is an unmet need for novel antivirals to battle SARS-CoV-2 and other coronaviruses. For this purpose, the development of peptidomimetics against the SARS-CoV-2 main protease (Mpro) and host proteases human cathepsin L (hCTSL) and cathepsin B (hCTSB) is an attractive strategy. These dual-mode antivirals target both viral entry and replication, which could be a suitable alternative to highly specific Mpro and CTS inhibitors. Herein, we examined the inhibitory activity, physicochemical and ADME properties, metabolic stability, and in vivo PK parameters of peptidomimetic inhibitors bearing a potent phenoxymethyl ketone warhead. Our compounds showed nanomolar inhibition of both Mpro and hCTSL/hCTSB and efficiently inhibited SARS-CoV-2 replication in cell culture. Furthermore, we studied metabolism and the impact of coadministration with the CYP-inhibitor ritonavir. Taken together, we report 1 as broad-spectrum coronavirus inhibitor with attractive properties to be pursued in in vivo efficacy studies.

1 October 2025 in bioRxiv
Verified
Preprint
Open access
IGIrene Georgiou
Irene Georgiou
CRColin Robinson
Colin Robinson
SOSean O’BYrne
Sean O’BYrne
AMAlex Matsuda
Alex Matsuda
PGPrzemysław Grygier
Przemysław Grygier
IGIan H. Gilbert
Ian H. Gilbert
SARS-CoV-2 non-structural protein 14 (nsp14) is essential for viral mRNA cap guanine-N7 methylation and represents a promising but underexplored antiviral target. Herein we describe a structure-guided campaign based on a hit from a focussed SAM mimetic library. Systematic SAR exploration guided by six X-ray co-crystal structures in complex with SARS-CoV-2 led to compound 26 , a bi-substrate inhibitor that bridges the SAM and RNA cap binding sites. Compound 26 achieved nanomolar potency against nsp14 from SARS-CoV-2 (IC 50 = 53 nM), SARS-CoV-1, and two alphacoronaviruses, with excellent selectivity over human RNMT and flaviviral MTase. In general, the compounds demonstrated favourable metabolic stability, passive permeability, and no HepG2 cytotoxicity. However, cellular antiviral activity was limited, revealing disconnects between enzyme inhibition and phenotypic response. These findings provide a structural framework for optimizing bi-substrate methyltransferase inhibitors against coronaviruses with a view for pan-coronaviral activity.